Local Coverage Determination (LCD)

Transthoracic Echocardiography (TTE)


Expand All | Collapse All
Proposed LCD
Proposed LCDs are works in progress that are available on the Medicare Coverage Database site for public review. Proposed LCDs are not necessarily a reflection of the current policies or practices of the contractor.

Document Note

Note History

Contractor Information

LCD Information

Document Information

Source LCD ID
Original ICD-9 LCD ID
Not Applicable
LCD Title
Transthoracic Echocardiography (TTE)
Proposed LCD in Comment Period
Source Proposed LCD
Original Effective Date
For services performed on or after 10/01/2015
Revision Effective Date
For services performed on or after 10/05/2023
Revision Ending Date
Retirement Date
Notice Period Start Date
Notice Period End Date
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.


Issue Description

Coverage and appropriate application of TTE, including stress echocardiography as outlined in the coverage and limitations section.

Issue - Explanation of Change Between Proposed LCD and Final LCD

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1862(a)(7) of Title XVIII of the Social Security Act excludes routine physical examination, unless otherwise covered by statute.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Code of Federal Regulations:

42 CFR, Section 410.32, indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements) and the results must be used in the management of the patient.

42 CFR 410.33 provides credentialing requirements for testing performed in an IDTF by technicians.

CMS Publications:

CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 9:

    100 General Billing Requirements

CMS Publication 100-04, Medicare Claims Processing Manual, Chapter 12:

    30.4 Cardiovascular System (Codes 92950-93799)

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity


Echocardiography is the ultrasonic examination of the heart. Transthoracic echocardiography (TTE) affords unique insight into cardiac structure and function. Two-dimensional (2D) imaging defines the configuration and changing dimensions of the chambers, dynamic cyclic variation in myocardial thickness, and the associated valvular motions throughout the cardiac cycle. The proximal great vessels and the pericardium can also be directly visualized, although transesophageal echocardiography (TEE) often permits better visualization of the thoracic aorta and great veins than does TTE. (ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography [hereafter referred to as the "ACC/AHA/ASE Guideline Update"], pg. 41).

A Doppler examination is a valuable adjunct to a complete echocardiographic examination. The basic principle utilizes the changes in frequency when a transmitted ultrasound wave is reflected from moving surfaces (e.g., heart valves, red blood cells), allowing the capability of measuring normal and abnormal velocities of blood flow. Such data may lead to the calculation of valvular stenosis, valvular regurgitation, cardiac output, intracardiac pressures or intracardiac shunts.

Some cardiac ultrasound machines have become increasingly compact and portable. Certain "hand carried" scanners are "full featured" and permit a skilled examiner to image and record permanent records of all of the tomographic images and Doppler data (both color and spectral) needed to perform a complete transthoracic echocardiographic examination that may be quite comparable, in diagnostic value, to that obtained with a larger, "state of the art" instrument. In order to qualify as a valid echocardiographic service, the study must be done for an accepted clinical indication by a properly trained examiner and must include a permanent record of the findings, data sufficient to support the conclusions and an appropriate interpretation and written report. Such a study would meet the standards required for a complete echocardiographic examination, regardless of the size of the instrument used to perform the study.

All echocardiography services require a referral or an order from a treating physician.

This policy addresses the medically necessary and appropriate application of TTE, including stress echocardiography. Transesophageal echocardiography (TEE) is the subject of a separate policy statement.


Echocardiography is indicated in the evaluation of derangements of valvular, myocardial and pericardial structure and function. The general applications for coverage include:

A. Transthoracic Echocardiogram


1. Ventricular Function, Cardiomyopathies and Heart Failure
Changes in myocardial thickness (hypertrophy and thinning), in derived parameters of contractility, and in chamber volume and morphology, can be quantitated and charted over time by TTE. Cardiac responses to volume perturbations, chronic pressure excess and therapeutic interventions can be monitored. Recognition of the relative contributions of myocardial and valvular functional perturbations to a clinical presentation is facilitated. TTE aids in the recognition of myopathies and their classification into hypertrophic, dilated and restrictive types. Absent clinically documented, discrete (abrupt change in signs and symptoms) episodes of deterioration, it is not generally medically necessary to augment clinical assessments with TTE measurements at more frequent than annual examinations.

There is increasing data to support the prognostic value of diastolic function parameters in patients with systolic dysfunction. "When the etiology is in doubt, echocardiography can document or rule out the common cardiac causes of pulmonary congestion: left-sided valvular disease, depressed systolic or diastolic function, and cardiomyopathy. In this regard, echocardiography is the preferred initial diagnostic test when the history, physical examination, and routine laboratory tests suggest (or cannot eliminate) cardiac disease." (ACC/AHA/ASE 2003 Guideline Update, pg. 35) "Echocardiography is recommended for patients with edema with clinical signs of elevated central venous pressure when a potential cardiac etiology is suspected or when central venous pressure cannot be estimated with confidence and clinical suspicion of heart disease is high." TTE is also recommended for patients experiencing "dyspnea with clinical signs of heart disease."(ACC/AHA/ASE 2003 Guideline Update, pg. 37) "Echocardiography is not recommended in patients with edema when the jugular venous pressure does not appear to be elevated." (ACC/AHA/ASE 2003 Guideline Update, pg. 35).

2. Hypertensive Cardiovascular Disease
"Echocardiography is the noninvasive procedure of choice in evaluating the cardiac effects of systemic hypertension, the most common cause of LV hypertrophy and congestive heart failure in adults." (ACC/AHA/ASE 2003 Guideline Update, pg. 42) Left ventricular hypertrophy (LVH) correlates with prognosis in hypertensive cardiovascular disease. However, "the usefulness of echocardiography in an individual patient with hypertension without suspected concomitant heart disease depends on the clinical relevance of the assessment of LV mass or function in that patient. Thus, not every patient with hypertension should have resting LV function assessed (Class I), but if such an assessment is relevant, echocardiography is a well-documented and accepted method by which to achieve it. The value of repeated studies in asymptomatic hypertensive patients with normal LV function is not clearly established." (ACC/ AHA 2003 Guideline Update, pg. 42).

Certain antihypertensive medications have been reported to stabilize and possibly contribute to the regression of left ventricular hypertrophy and the insidiously progressive development of left ventricular dysfunction and dilatation. In young individuals and in individuals with borderline hypertension, the decision to commit to long-term antihypertensive therapy may be determined by the presence of left ventricular hypertrophy and /or left ventricular mass calculation.

3. Acute Myocardial Infarction and Coronary Insufficiency
TTE can detect ischemic and infarcted myocardium. Regional motion, systolic thickening perturbations and mural thinning can be quantitated and global functional adaptation assessed. The relative contributions of right ventricular ischemia and/or infarction can be evaluated. Complications of acute infarction (e.g., mural thrombi, papillary muscle dysfunction and rupture, septal defects, true or false aneurysm and myocardial rupture) can be diagnosed and their contribution to the overall clinical status placed in perspective. Following an initial TTE in the setting of acute infarction, repetition frequency will typically be dictated by the acute clinical course. The medical record should document the medical necessity of the frequency for TTE assessment.

"Evaluation of chest pain in patients with suspected acute myocardial ischemia, when baseline ECG and other laboratory markers are nondiagnostic and when study can be obtained during pain or within minutes after its abatement" is recommended in the ACC/AHA/ASE 2003 Guideline Update. "The use of echocardiography for diagnosis of acute myocardial infarction provides the greatest amount of incremental information when the clinical history and ECG findings are nondiagnostic." (ACC/AHA/ASE 2003 Guideline Update, pg. 15) This application may be used as part of a thoughtful clinical evaluation, especially as a triage decision on chest pain syndrome.

4. Exposure to Cardiotoxic Agents (chemotherapeutic and external)
Measures of myocardial contractility, thinning and dilatation are important in the titration of therapeutic agents with known myocardial toxicity. When echocardiography is used to monitor cardiac toxicity of chemotherapeutic agents (e.g., degenerative cardiomyopathy produced by doxorubicin therapy), an initial complete TTE may be performed prior to first administration of the agent with the frequency of repeat studies determined by the patient's clinical course and the toxicity profile of the agent being administered, although tests performed bimonthly during chemotherapy and at six (6) months following therapy are generally considered medically appropriate.

5. Cardiac Transplant and Rejection Monitoring
TTE is an integral part of the cardiac donor-selection and donor-recipient matching process. Evaluation focuses on analysis of ventricular function and valvular integrity. TTE is also incorporated into the management of allograft recipients. Myocardial thickness, refractile properties, contractile patterns and indices, restrictive hemodynamics, and the late development of pericardial fluid may alert the clinician to a rejection episode. None of these findings has achieved diagnostic sensitivity or specificity. Typically, TTE is performed weekly for the first four to eight (4-8) weeks following transplant, with decremental frequency over time. Absent acute rejection episodes, approximately two (2) TTE examinations are typically performed yearly in chronic transplant recipients. TTE of cardiac allografts is most appropriately serially performed at transplant centers by examiners with expertise in the management of cardiac allograft recipients. Uses in excess of the generally accepted frequency will be expected to have appropriate medical necessity documentation provided.

6. Native Valvular Heart Disease
TTE is well established as a technique of primary choice for the evaluation of valvular pathology and its effect upon global myocardial function. The relative severity of multi-valve pathologies can be quantified. Visualization of the valve and valvular apparatus facilitates therapeutic decisions when competing therapeutic options exist. For example, noninvasive TTE remains the study of choice for monitoring chronic aortic pathology with images suitable for serial quantitation. In some patients, Doppler echocardiography is the only noninvasive method capable of identifying the cause of a heart murmur. (ACC/AHA/ASE 2003 Guideline Update, pg. 7) Absent acute intervention, or a discrete change in otherwise stable clinical signs and symptoms, it is not medically necessary to repeat these examinations more frequently than annually. when the patient's clinical status shows evidence of change or the plan of care includes consideration for imminent valvular surgery, more frequent exams may be necessary.

7. Prosthetic Heart Valves (Mechanical & Bio-prostheses)
TTE assessment soon after prosthetic valve implant is important in establishing a baseline structural and hemodynamic profile unique to the individual and the prosthesis. Size, position, underlying ventricular function and concomitant valve pathologies all impact this unique profile. Reassessment following convalescence (3-6 months) for establishment of a baseline is appropriate. Thereafter, re-evaluation of patients with suspected dysfunction, thrombosis or a change in clinical status or symptoms is indicated.

8. Acute Endocarditis
TTE can provide diagnostic information; larger vegetations may be directly visualized; and valvular anatomy and ventricular function directly assessed. The complications or sequelae of acute infective endocarditis can be detected and monitored over time. Examination frequency in the acute phase of illness is dictated by the individual clinical course. When the acute process has been stabilized, the frequency of serial TTE evaluation will be determined by the residual pathophysiology and discrete clinical events, analogous to the serial assessment of chronic valvular dysfunction and/or normally functioning prosthetic valves.

9. Pericardial Disease
Detection and quantitation of the amount of pericardial effusion were among the first, and remain important, applications of TTE. Pericardial fluid accumulations of as little as twenty (20) milliliters have been reliably diagnosed by TTE. Cardiac motion and blood flow patterns demonstrated by TTE characterize the hemodynamic consequences of pericardial fluid accumulation. A collage of TTE findings has been found to be reliable indices of cardiac tamponade. TTE can be a valuable adjunct during the removal of pericardial fluid and creation of pericardial windows. The acute clinical status will dictate examination frequency. In a patient with evolving pericardial pathology, a limited focused TTE exam may be appropriate. TTE and Doppler techniques are quite helpful in identifying pericardial constriction and differentiating it from restrictive myocardial disease.

10. Abnormalities of the Great Vessels
Aorta: TTE can provide valuable information when acute or chronic aortic pathology is present; however, the posterior window of TEE, coupled with the more posterior position of the thoracic aorta, has rendered TEE a more determinative study. Noninvasive TTE remains the study of choice for chronic aortic pathology when images suitable for serial quantitation can be obtained. Routine (yearly) evaluation is indicated in patients with severe aortic stenosis or regurgitation, in whom the information obtained will be used in determining or modifiying the plan of care. In some individuals, such as those with ascending aortic dilatation or aneurysms, a focused limited follow-up exam (93308) to serially measure ascending aortic diameters may be indicated. Although TTE may visualize the intimal flap in patients with aortic dissection, TEE has proved to be a far more sensitive diagnostic procedure. TEE is the technique that is indicated in examination of the entire aorta, especially in emergency situation.
Pulmonary Artery: It is also indicated for visualization of the main pulmonary artery segment and the proximal right and left pulmonary arteries.

Venae Cavae: Echocardiography is indicated for visualizing the vena cavae and diagnosing various congenital and acquired abnormalities such as vena caval thrombosis, vena caval dilation, and thrombosis or extension of tumors from the inferior vena cava to the right-heart chambers.

11. Congenital Heart Disease
In children and small adults TTE provides accurate anatomic definition of most congenital heart diseases. Coupled with Doppler hemodynamic measurements, TTE usually provides accurate diagnosis and noninvasive serial assessment. A technically adequate TTE can obviate the need for preoperative catheterization in select individuals. When the disease process and therapy are stable, serial assessment by TTE requires contemporaneous medical necessity documentation, if the frequency exceeds an annual evaluation. In asymptomatic patients following repair of ASD, PFO, VSD or PDA follow up examination is only indicated within the first year after correction.

12. Suspected Cardiac Thrombi and Embolic Sources
TTE is indicated for the evaluation for cardiovascular source of embolic events (PFO/ASD, atrial or ventricular thrombus, intracardiac tumor) in evaluation for patients with abrupt occlusion of a major peripheral or visceral artery or for with neurological events without evidence of cerebrovascular disease or other obvious cause. Limited visualization of atrial appendages and the more peripheral and superior portions of the atria render TTE less sensitive than TEE in the detection of atrial thrombus and potentially embolic material. In those instances where the precise diagnosis and localization of potentially embolic material is of paramount therapeutic importance and the information so obtained will potentially and substantively alter therapy, or the risk of anticoagulants is inordinately high, consideration should be given to TEE if TTE provides inadequate decisional information.

13. Cardiac Tumors and Masses
Infiltrative and ventricular tumors and masses can be visualized, their extent quantitated and their hemodynamic consequences assessed by TTE. Right atrial space-occupying masses are usually well visualized by TTE. TEE provides a more detailed view of the left atrium and is more sensitive in quantifying mass characteristics (solid, cystic, etc.), extensions and attachments. Serial TTEs may be medically necessary to monitor tumor size or tumor recurrence.

14. Critically Ill and Trauma Patients
There is a role for echocardiography in the management of critically ill patients and trauma victims. The diagnosis of suspect aortic or central pulmonary pathology, cardiac contusion, or a pericardial effusion may be confirmed. Perturbations of volume status may be more completely defined and management strategies modified. The frequency of these typically acute studies will be dictated by the exigencies of the clinical milieu.

15. Arrhythmias and Palpitations
Transthoracic echocardiography is useful in defining cardiac function in which arrhythmias occur, and may be useful in the management of cardiac arrhythmias. Some arrhythmias are frequently associated with underlying organic heart disease or may predispose the patient to hemodynamic deterioration. Atrial fibrillation and atrial flutter are examples of arrhythmias in which echocardiography may be appropriate to assess the underlying disorder. Echocardiographic studies are appropriate only when there is evidence of heart disease. Palpitations without evidence of arrhythmias, or minor arrhythmias (e.g., isolated APC's or VPC's) without evidence of heart disease, are not covered indications for transthoracic echocardiography.

16. Syncope
Determination of the etiology of syncopal episodes can be a difficult clinical problem. The origin may be cardiac, neurological, or due to other causes. Syncope due to cardiac origin is most commonly related to vasodepressor reflexes, bradyarrhythmias, or tachyarrhythmias. Syncope is less commonly caused by cardiac structural disorders. Patients with a structurally normal heart generally have a much more benign prognosis than those with underlying structural coronary artery disease or cardiomyopathic disease. Echocardiography is only appropriate as the initial evaluation, and when other findings are suggestive of valvular heart disease or obstructive cardiomyopathy.

17. Pulmonary
Pulmonary heart disease may result from acute changes in the pulmonary circulation (e.g., pulmonary embolus), or chronic changes produced by chronic hypoxia which may cause significant right ventricular dysfunction and hypertrophy. Echocardiography may assess right ventricular size and performance, and quantify the severity of pulmonary hypertension using Doppler interrogation of valvular flow signals. Indications include unexplained pulmonary hypertension, and pulmonary emboli with suspected right atrial or right ventricular sources of emboli.

18. Contrast Echocardiography
Contrast echocardiography is indicated when a conventional study has failed to provide adequate and critically needed information on left ventricular function. A contrast agent is considered medically necessary when it is used to improve the delineation of the left ventricular endocardial borders in a patient whose non-contrast study is inadequate or suboptimal, and for whom the LV function information is essential to the management of the patient. Contrast is indicated when more than two (2) contiguous segments of the left ventricular border are not visualized.

19. CAMZYOS™ (mavacamten) treatment
Patients with symptomatic obstructive hypertrophic cardiomyopathy NYHA Class II-III may be prescribed mavacamten by a certified and enrolled provider and pharmacy through a restricted program called the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) program.1,2 This requirement is due to serious risk of heart failure due to systolic dysfunction associated with this agent in this population, however there are few options for treatment and improvement in health status on this agent in select patients leading to the REMS program to provide treatment while furthering understanding of the risk: benefit ratio.1,3,4This program requires echocardiograms at:
i. Prior to enrollment
ii. 4, 8, and 12 weeks after treatment initiation, then every 12 weeks thereafter
iii. 4 weeks after interruption of treatment
iv. 4 and 12 weeks after any dose change (including restart of treatment)
v. 4 and 12 weeks after initiating a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor


    1. Echocardiography performed for screening purposes is not covered. Screening includes testing performed on patients who present with risk factors (including the risk factor as having a positive family history, e.g., familial history of Marfan's disease). A screening service for high-risk patients is considered good medical practice but is not covered by Medicare. When the result of the test is abnormal, subsequent services may be billed with the test-result diagnosis; however, the initial screening test must be listed as screening, even though the result of the screening test may be a covered condition.

The following indications (#2-15) are deemed to be not medically necessary and are therefore not reimbursable:

2. Routine (yearly) evaluation of asymptomatic patients with corrected ASD, VSD or PDA more than one year after successful correction.

3. Routine (yearly) re-evaluation of mitral valve prolapse in patients with no or mild mitral regurgitation and no change in clinical status.

4. Routine (yearly) re-evaluation of an asymptomatic patient with mild native aortic stenosis or mild-moderate native mitral stenosis and no change in clinical status.

5. Routine (yearly) re-evaluation of native valvular regurgitation in an asymptomatic patient with mild regurgitation, no change in clinical status and normal left ventricular size.

6. Routine (yearly) evaluation of a patient with a prosthetic valve in whom there is no suspicion of valvular dysfunction and no change in clinical status.

7. Routine (yearly) re-evaluation of patients with heart failure (systolic or diastolic) in whom there is no change in clinical status.

8. Routine (yearly) evaluation of hypertrophic cardiomyopathy in a patient with no change in clinical status.

9. Patients who have isolated APC or VPC without other evidence of heart disease.

10. Evaluation of LV function with prior ventricular function within the past year with normal (such as prior echocardiogram, left ventriculogram, SPECT, cardiac MRI) in patients in whom there has been no change in clinical status.

11. Initial evaluation of patient with suspected pulmonary embolism in order to establish diagnosis.

12. Evaluation of native and/or prosthetic valves in patients with transient fever but without evidence of bacteremia or new murmur.

13. Re-evaluation of a patient with known hypertensive heart disease without a change in clinical status.

14. Routine evaluation of patients with systemic hypertension without suspected hypertensive heart disease.

15. Evaluation of a patient with atrial fibrillation/flutter for left atrial thrombus or spontaneous contrast when a decision has been made to anticoagulate and not to perform cardioversion.

[Items 2-15, see ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 Appropriateness Criteria for Transthoracic and Transesophageal Echocardiography, JACC 2007].
16. Echocardiograms for symptomatic obstructive hypertrophic cardiomyopathy and administration of mavacamten must be enrolled in the FDA CAMZYOS REMS program2 and meet all requirement of this program. Echocardiograms used outside of the protocol will not be covered.
B. Follow-up Studies or Limited Studies


A complete study includes a full evaluation of all aspects of the heart, including the cardiac chambers, valves, blood flow, and great vessels. The images are reviewed, measured, analyzed and interpreted by the physician. A report is prepared for the patient's record. When a less than complete examination is performed for the purpose of evaluation of one specific cardiac problem, or region of the heart, the service performed is described by codes 93304, 93308 and 93321, follow-up or limited studies. When a limited service is performed, or the patient's condition requires only a limited examination, these codes must be used to indicate the appropriate service.

Examples of appropriate use of 93308: a follow-up study of a patient with pericardial effusion following heart surgery, to evaluate progression or resolution of the effusion; or a serial evaluation of left ventricular function during antineoplastic chemotherapy.

Examples of appropriate use of 93321: recording tricuspid regurgitant velocity in order to estimate pulmonary artery systolic pressure; or sequential evaluation of the transmitral velocity profile in a patient with mitral stenosis, in order to evaluate for a change in gradient or valve area.

C. Doppler Color Flow Velocity Mapping

Spectral Doppler echocardiography and Doppler color flow-velocity mapping (93320, 93321, 93325) may be necessary in addition to an echocardiogram when the examination could contribute significant information to the patient's condition or treatment plan (For Dates of service on or after 01/01/2009, code 93306 should be used when Doppler is combined with a complete echocardiogram). Typically, Doppler is indicated in the evaluation of some heart murmurs, valvular problems, shunts, suspected congenital heart disease, complications of myocardial infarction, or cardiomyopathy. Doppler should be medically necessary for the evaluation and management of the patient.

"Color/spectral Doppler may not be useful or appropriate in certain relatively small and well-defined patient populations when there is a recent comprehensive examination and the test is being ordered for re-evaluation of a limited problem." (ASE comment).

The use of the Doppler is inherent in the ultrasonic cardiac evaluation. However, if the test reports fail to document the use of this technique to assess these structures and function (e.g., measurement of valvular insufficiency or stenosis, myocardial diastolic function, etc. as described by the ASE), or if the medical records fail to document that the examination was "clinically necessary" (e.g., follow-up of pericardial effusion size) then the Doppler portion of the test may be considered medically unnecessary and denied.

D. Limited Capability Ultrasound Scanners


Some small scanners have more limited capabilities and lack either the permanent recording capabilities or some of the functional capabilities needed to perform a complete examination. Such a study may be quite useful as an extension of the physical examination. However, an examination that does not meet the standards required for a complete diagnostic echocardiographic examination – whether performed with a "conventional" scanner or a limited capability ultrasound scanner - will not be recognized as a valid echocardiographic service and will be non-covered.

E. Stress Echocardiography

Stress Echocardiography may be necessary when the evaluation could contribute significant information to the patient's condition or treatment plan. A nonimaging stress test focuses on the hemodynamic and electrocardiographic responses to stress. To enhance the diagnostic specificity, the stress test may be combined with echocardiographic imaging or scintigraphic imaging. A contrast agent may be used with echocardiographic imaging to enhance endocardial visualization and diagnostic accuracy. When two (or more) imaging studies (e.g., ultrasound and scintigraphy) are billed without a supporting clinical indication for each, one of the services will be denied as not medically necessary.
This section addresses the echocardiographic imaging that is done in association with a stress test.


Stress echocardiography may be indicated in the care of patients with real or suspected ischemic heart disease in the following clinical settings:

  • To detect coronary artery disease in patients presenting with chest pains including atypical chest pains and exertional dyspnea when the suspicion of CAD is high.
  • To assess prognosis and functional capacity in patients following an acute myocardial infarction.
  • To evaluate the extent of exercise induced ischemia in patients who have had a revascularization procedure (PCTA, stent or coronary bypass) or patients who have known CAD disease.
  • In women, stress imaging has been recommended as the "initial test."
  • To evaluate a prior nondiagnostic or abnormal ECG exercise test as a substitute for a nuclear perfusion study.
  • To evaluate patients who are at high risk for myocardial infarction prior to a scheduled major surgical procedure (e.g., aneurysm, vascular surgery, surgeries with large volume shifts, etc) or transplant procedure.
  • To evaluate patients presenting with various arrhythmias (atrial and/or ventricular) or syncope (near or pre), when the suspicion of occult coronary artery disease is high.
  • To evaluate patients when an indicated standard exercise ECG is likely to be non-diagnostic, including patients with an abnormal resting ECG, orthostatic or hyperventilation induced ECG changes, non specific ST-T abnormalities due to ventricular hypertrophy drugs or associated intraventricular conduction defect.
  • To assess myocardial viability (hibernating myocardium) for planned revascularization or functional significance of coronary lesions (if not already known) in planning percutaneous transluminal coronary angioplasty.
  • To evaluate cardiomyopathy when the evaluation could reasonably be expected to contribute significant information regarding the patient'’s condition or treatment plan.
  • To evaluate ventricular dysfunction due to post-transplant rejection when the evaluation could reasonably be expected to contribute significant information regarding the patient's condition or treatment plan.
  • To evaluate congenital heart disease, when stress echocardiography helps to determine systemic and right ventricular function at rest and following stress and the presence of any other structural abnormalities, including valvular lesions that may be accentuated with stress.
  • Additionally the test may combined with Doppler intervention to evaluate exercise hemodynamics in patients with mitral stenosis, mitral regurgitation, pulmonary hypertension, aortic stenosis/regurgitation, prosthetic valves and other conditions where symptoms suggest a more severe impairment than the assessment done at rest.
  • Dobutamine stress echo may be indicated to detect low gradient, low output (aortic stenosis) or clinically silent transplant coronary disease.
    • Stress echocardiography used as a screening test for ischemic heart disease in a patient without signs or symptoms is not covered.
    • "An echocardiographic study is not indicated when the pathology and/or systolic ventricular function have been adequately defined by other techniques, making the echocardiographic study redundant." (ACC/AHA/ASE 2003 Guideline Update, pg. 5) Since echocardiography, nuclear testing, magnetic resonance imaging (MRI), and positron emission tomography can yield overlapping if not identical information, often with similar or comparable accuracy, when two or more of these tests provide equivalent information, one (but not both/all) will be covered when medically necessary. Stress tests by multiple modalities (e.g. stress echocardiography, nuclear SPECT) for the same clinical event are covered only if the preceding test was inconclusive or uninterpretable.
    • Studies with or without contrast will be considered a single study, whether performed on the same or subsequent days.
    • Contrast echocardiography is not covered when used to evaluate perfusion. Contrast is not indicated unless more than two (2) contiguous segments of the left ventricular border are not visualized.
    • A stress test must be ordered by a physician or qualified non-physician provider.
    • The resting 12 lead EKG and rhythm strip are considered to be part of the stress test. These services are not separately reimbursable.
    • The initiation of an intravenous line and infusion of a pharmacological agent are considered to be a part of the test, and are not separately reimbursable.
      Stress testing should be conducted by well trained personnel. Only technicians and physicians familiar with normal and abnormal responses during exercise are trained to recognize or prevent untoward events. Equipment, medications and personnel trained to provide cardiopulmonary resuscitation (CPR) must be readily available.
    • F. 3-Dimensional Echocardiography


      New techniques for the 3-dimensional echocardiography have been reported. Initially these reports are mostly related to mitral valve dysfunction (stenosis and prolapse) and measurement of left ventricular volumes. Three-dimensional echocardiography appears to be of clinical value in the pre-operative planning of mitral valve repair for prolapse, and the accurate calculation of mitral valve area. Although it provides improved calculation of volumetric studies when compared to 2D echocardiography, when compared to cardiac MRI, its value in affecting clinical outcomes is not yet proven. When performed in conjunction with transthoracic echocardiography (93303, 93304, 93306, 93307, 93308) it is indicated only for pre-operative planning in those patients in whom surgery is already planned and for monitoring the mitral valve area in patients with moderate to severe mitral stenosis.

      G. Training Requirements

      While it is not the Contractor's intention or jurisdiction to credential providers, Medicare does expect a satisfactory level of competence from providers who submit claims for services rendered. It is well known that substandard studies often lead to preventable repetition of studies and overutilization of services.

      The acceptable levels of competence are outlined as follows:

      For the technical portion
          , an acceptable level of competence is fulfilled when the image acquisition is obtained under any one of the following conditions:

        • The service is performed by a physician; or

        • The technical service is performed by an individual who is credentialed as either a Registered Diagnostic Cardiac Sonographer (RDCS) through the American Registry of Diagnostic Medical Sonographers or as a Registered Cardiac Sonographer (RCS) through the Cardiovascular Credentialing International; or

        • The service is performed at a laboratory (e.g. office, IDTF), credentialed by the Intersocietal Commission for the Accreditation of Echocardiography Laboratories (ICAEL). Any non-physician personnel used by an IDTF to perform tests must demonstrate the basic qualifications to perform the tests in question and have training and proficiency as evidenced by licensure or certification by the appropriate State health or education department. In the absence of a State licensing board, the technician must be certified by an appropriate national credentialing body. The IDTF must maintain documentation available for review that these requirements are met.

        • For the professional portion, an acceptable level of competence is fulfilled when the interpretation is performed by a physician meeting any one of the following requirements:

          • The physician is board certified in Cardiovascular Diseases; or

          • The physician has Level II training in transthoracic echocardiography, as defined by the American College of Cardiology/American Heart Association/ American College of Physicians Task Force on Clinical Competence in Echocardiography, or the equivalent of Level II training as set forth in that document.

          • For Facilities, quality requirements should encompass approved ACC/AHA/ASE training standards for physicians, accreditation by ICAEL for facilities, and certification of cardiac sonographers by recognized national credentialing organizations as the appropriate quality standards.
          The submission of claims for echocardiography will be considered an attestation that both the technical and professional components of the service were provided within the context of the above stated credentials.

          CGS providers submitting claims for these services will be allowed a 2-year grace period (until 07/01/2011) to meet these standards.

          Other Comments:

          For claims submitted to the Part A MAC: this coverage determination also applies within states outside the primary geographic jurisdiction with facilities that have nominated CGS Administrators, LLC to process their claims.

          Bill type codes only apply to providers who bill these services to the Part A MAC. Bill type codes do not apply to physicians, other professionals and suppliers who bill these services to the carrier or Part B MAC.

          Limitation of liability and refund requirements apply when denials are likely, whether based on medical necessity or other coverage reasons. The provider/supplier must notify the beneficiary in writing, prior to rendering the service, if the provider/supplier is aware that the test, item or procedure may not be covered by Medicare. The limitation of liability and refund requirements do not apply when the test, item or procedure is statutorily excluded, has no Medicare benefit category or is rendered for screening purposes.

          For dates of service prior to April 1, 2010, FQHC services should be reported with bill type 73X. For dates of service on or after April 1, 2010, bill type 77X should be used to report FQHC services.

          For outpatient settings other than CORFs, references to "physicians" throughout this policy include non-physicians, such as nurse practitioners, clinical nurse specialists and physician assistants. Such non-physician practitioners, with certain exceptions, may certify, order and establish the plan of care as authorized by State law. (See Sections 1861[s][2] and 1862[a][14] of Title XVIII of the Social Security Act; 42 CFR, Sections 410.74, 410.75, 410.76 and 419.22; 58 FR 18543, April 7, 2000.)
Summary of Evidence


Analysis of Evidence (Rationale for Determination)

The policy is updated to address echocardiograms for symptomatic obstructive hypertrophic cardiomyopathy and administration of mavacamten (CAMZYOS) as enrolled in the FDA CAMZYOS REMS program2 and meet all requirement of this program. 

Proposed Process Information

Synopsis of Changes
Changes Fields Changed
Associated Information
Sources of Information
Open Meetings
Meeting Date Meeting States Meeting Information
Contractor Advisory Committee (CAC) Meetings
Meeting Date Meeting States Meeting Information
MAC Meeting Information URLs
Proposed LCD Posting Date
Comment Period Start Date
Comment Period End Date
Reason for Proposed LCD
Requestor Information
This request was MAC initiated.
Requestor Name Requestor Letter
Contact for Comments on Proposed LCD

Coding Information

Bill Type Codes

Code Description

Revenue Codes

Code Description


Group 1

Group 1 Paragraph


Group 1 Codes



ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph:


Group 1 Codes:



ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph:


Group 1 Codes:



Additional ICD-10 Information

General Information

Associated Information

The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures, as well as reasons for repeat testing.

Each service requires a formal written report with interpretation. This report should be kept on file with copies of image documentation (paper or tape) for review if requested. All appropriate measurements should be included in the report.

At a minimum, a complete study should contain M mode and/or 2D measurements of LV end diastolic diameter, LV end systolic diameter, LV wall thickness, left atrial diameter, aortic valve excursion and a qualitative description of the LV function, whenever possible given any technical limitations in a particular case. Individual echocardiographic laboratories (providers) may choose valid substitutes for these parameters such as LV volumes, ejection fraction and mass measurements.

A Doppler interrogation should state the modes used and should give both qualitative and quantitative information.

Claims for contrast echocardiography services must be supported by documentation that conventional studies were inconclusive and there was a need for the contrast enhancement.

The medical record should clearly document the reasons for performing multiple tests, as well as prior data which has been reviewed. If specific prior test results were requested and not received, necessitating repeat or additional testing, then this should also be noted in the records.

In the case of disease processes that could preclude the performance of exercise stress testing, the medical documentation should clearly describe why the patient cannot perform exercise stress testing. The documentation must include (but is not limited to) history and physical exam findings demonstrating that the patient could not reasonably be expected to perform exercise stress testing.

Documentation of the qualifications of personnel performing tests, as described in the Indications section of the LCD, should be available on request.

In those instances in which repeat tests were denied, the physician must document a good faith effort was made to identify them and to request copies of them from previous providers, in order for CGS to consider reimbursement for such tests on appeal.

Documentation must be available to Medicare upon request.

Not applicable

Repeat echocardiographic studies should be guided by the clinical status of the patient. The frequency of services is guided by the circumstances outlined in the Indications and Limitations section of this policy. Repeat studies are appropriate to monitor changes in cardiac structure or function when there are changes in the clinical status of the patient, or when disease progression is otherwise suspected.

Services performed in the Emergency Room and other emergency services are excluded from any frequency limitations on coverage for repeat testing. While Emergency Room services would be identified on the claim by the place of service code (23), emergency services provided at other sites would require post-pay review of the documentation provided in the medical record.

In those instances in which repeat tests were denied and a physician has documented a good faith effort to identify them and to request copies of them from previous providers, then CGS could reimburse such tests on appeal.

Sources of Information
  1. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 Appropriateness criteria for transthoracic and transesophageal echocardiography, downloaded from http://www.acc.org/qualityandscience/clinical/pdfs/TTE.TEE.pdf. Accessed February 24, 2007.
  2. AHA Position Statement, Cardiac transplantation: recipient selection, donor procurement, and medical follow-up. Circulation. 1992;86(3): 1061-1079.
  3. American College of Cardiology, Guidelines for the Clinical Application of Echocardiography. www.acc.org.
  4. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, PA: W.B. Saunders Company;2001.
  5. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE/ASE 2003 guideline update for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/ASE/ASE Committee to update the 1997 guidelines for the clinical application of echocardiography). 2003. http://www.acc.org/qualityandscience/clinical/guidelines/echo/index_clean.pdf. Accessed February 24, 2007.
  6. CMD Cardiology Work Group.
  7. CPT Assistant, Volume 7, issue 12, December 1997:5-6.
  8. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 Appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation appropriateness criteria task force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance endorsed by the Heart Rhythm Society and the Society of Critical Care Medicine. J. Am. Coll. Cardiol. 2008;51;1127-1147; originally published online Mar 3, 2008; doi: 10.1016/j.jacc.2007.12.005
  9. Hung J, Lang R, Flachskampf F, et al. 3D echocardiography: a review of the current status and future directions. J. Am. Soc Echocardiography. 2007; 20:213-233.
  10. LMRP Workgroup, American College of Cardiology and American Society of Echocardiography.
  11. Otto C. The Practice of Clinical Echocardiography. 2nd ed. Philadelphia, PA: W.B. Saunders Company;2002.
  12. Pepi M, Tamborini G, Maltagliati A, et al. Head-to-head comparison of two-and three-dimensional transthoracic and transesophageal echocardiography in the localization of mitral valve prolapse. J Am Coll Cardiol. 2006; 48:2524-2530.
  13. Quinones MA, Douglas PS, Foster E, et al. ACC/AHA clinical competence statement on echocardiography. Journal of the American College of Cardiology. 2003;41.4:687-708.
  14. Schiller N. Protocols for stress echocardiography in coronary heart disease, UpToDate, online 13.1. www.uptodate.com.
  15. Stress Echocardiography policies from Transamerica Occidental Life AZ, NV, HI, OR, WA, AK, effective date February 10, 1997; and Florida, effective date April 17, 1995.

This bibliography presents those sources that were obtained during the development of this policy. CGS Administrators, LLC is not responsible for the continuing viability of Web site addresses listed below.

Revision History Information

Revision History Date Revision History Number Revision History Explanation Reasons for Change
10/05/2023 R20


Revision Effective: 10/05/2023

Revision Explanation: Annual review, no changes were made. 

  • Other (Annual Review)
05/28/2023 R19


Revision Effective: 05/28/2023

Revision Explanation: Released draft to final to begin notice period.

  • Provider Education/Guidance
10/06/2022 R18


Revision Effective: 10/06/2022

Revision Explanation: Annual Review, no changes made

09/26/2022: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
09/30/2021 R17


Revision Effective: 09/30/2021

Revision Explanation: Annual Review, no changes made

09/22/2021: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
09/26/2019 R16


Revision Effective: N/A

Revision Explanation: Annual Review, no changes made

09/15/2020: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual review)
09/26/2019 R15


Revision Effective: 09/26/2019

Revision Explanation: Annual Review, no changes made

09/26/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review, no changes made)
09/26/2019 R14


Revision Effective: 09/26/2019 Revision Explanation: Converted to new policy template that no longer includes coding section based on CR 10901.

09/20/2019:At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To Code Removal
10/01/2018 R13


Revision Effective: N/A

Revision Explanation: Added note for ICD-10 group 3 and 4-(When reporting add-on CPT codes 93320, 93321 and 93325, the same ICD-10-CM code should be used as that used for the base code to which it is attached).

11/13/2018-At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.


  • Request for Coverage by a Practitioner (Part B)
10/01/2018 R12


Revision Effective: N/A

Revision Explanation: Annual review no changes made.

09/27/2018-At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Other (Annual Review)
10/01/2018 R11


Revision Effective:10/01/2018

Revision Explanation: During the annual ICD-10 update codes I63.8 and T81.4XXA were deleted and replaced with the following: I63.81, I63.89, T81.40XA, T81.40XD, T81.40XS, T81.41XA, T81.41XD, T81.41XS, T81.42XA, T81.42XD, T81.42XS, T81.43XA, T81.43XD, T81.43XS, T81.44XA, T81.44XD, T81.44XS, T81.49XA, T81.49XD, and T81.49XS. the following new codes were added based on annual review: I67.850, I67.858, T43.641A, T43.641D, T43.641S, T43.642A, T43.642D, T43.642S, T43.643A, T43.643D, T43.643S, T43.644A, T43.644D, and T43.644S.


At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.


Revision Effective: N/A
Revision Explanation: Annual review no changes made.

  • Revisions Due To ICD-10-CM Code Changes
10/01/2017 R10

Revision #: R10
Revision Effective: 10/01/2017
Revision Explanation: During ICD-10 annual update codes E85.8 and I27.2 were deleted from group 1 and replaced with E85.81, E85.82, E85.89, I27.20, I27.21, I27.22, I27.23, I27.24, I27.29. New codes were also added to group1 I27.83, I21.A1, and I21.A9.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To ICD-10-CM Code Changes
10/01/2016 R9 Revision #: R9
Revision Effective: N/A
Revision Explanation: Annual review no changes made.
  • Other (Annual review)
10/01/2016 R8 Revision #: R8
Revision Effective: 10/01/2016
Revision Explanation: During ICD-10 annual update I60.21, I60.22 Q25.2, Q25.4, and Z98.89 were deleted. The replacement code and description fro I60.21 and I60.22 was not added as CGS feels this is not a fit for the policy. Codes Q25.21, Q25.29, Q25.41-Q25.49, Z98.890, and Z98.891 were added from the ICD-10 annual update.
  • Revisions Due To ICD-10-CM Code Changes
01/01/2016 R7 Revision #: R7
Revision Effective: 01/01/2016
Revision Explanation: Added R4020 to group one as diagnosis that meets medical necessity.
  • Reconsideration Request
10/01/2015 R6 Revision #: R6
Revision Effective: 10/01/2015
Revision Explanation: added Z01.810 to group one.
  • Reconsideration Request
10/01/2015 R5 Revision #: R5
Revision Effective: 10/01/2015
Revision Explanation: Annual review no changes made.
  • Other (Annual Review)
10/01/2015 R4 Revision #: R4
Revision Effective: 10/01/2015
Revision Explanation: accepted revenue code description changes
  • Other (revenue code description change)
10/01/2015 R3 Revision #: R3
Revision Effective: 10/01/2015
Revision Explanation: HCPCS code J0151 was replaced with code J0153 during the 2015 annual change.
  • Revisions Due To CPT/HCPCS Code Changes
10/01/2015 R2 Revision #: R2
Revision Effective: 10/01/2015
Revision Explanation: Added ICD-10 Z52.4 to group one for codes 93306, 93307, 93308, 93320, 93321, 93325, C8923, C8924, and C8929.
  • Request for Coverage by a Practitioner (Part B)
10/01/2015 R1 Revision #: R1
Revision Effective: 10/01/2014
Revision Explanation: T40.1X5A and T40.8X5A are not valid for 2014 and have been remove. These codes had no replacement.
  • Revisions Due To ICD-10-CM Code Changes

Associated Documents

Related National Coverage Documents
Public Versions
Updated On Effective Dates Status
09/29/2023 10/05/2023 - N/A Currently in Effect You are here
04/06/2023 05/28/2023 - 10/04/2023 Superseded View
09/26/2022 10/06/2022 - 05/27/2023 Superseded View
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.



Read the LCD Disclaimer